Systematic review of factors affecting the ratios of morphine and its major metabolites

Pain

Volumn 74, Issue 1, 1998, Pages 43-53

  Faura, Clara C ^a   Collins, Sally L ^b   Moore, R Andrew ^b   McQuay, Henry J ^b  

^a INSTITUTO DE NEUROCIENCIAS   (Spain)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Morphine; Morphine 3 glucuronide; Morphine 6 glucuronide; Systematic review

Indexed keywords

DRUG METABOLITE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE;

ADOLESCENT; ADULT; AGE; ARTICLE; BUCCAL DRUG ADMINISTRATION; CHILD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG GLUCURONIDATION; DRUG METABOLISM; EPIDURAL DRUG ADMINISTRATION; FIRST PASS EFFECT; HUMAN; INFANT; INTRAMUSCULAR DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; NEWBORN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLABIAL DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0031933116     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(97)00142-5     Document Type: Review

References (53)

1. Aherne W.G., Littleton P. Morphine-6-glucuronide, an important factor in interpreting morphine radioimmunoassays. Lancet. 2:1985;210-211.
2. Ball M., McQuay H.J., Moore R.A., Allen M.C., Fisher A., Sear J. Renal failure and the use of morphine in intensive care. Lancet. 1:1985;784-786.
3. Bodd E., Jacobsen D., Lund E., Ripel A., Morland J., Wiik-Larsen E. Morphine-6-glucuronide might mediate the prolonged opioid effect of morphine in acute renal failure. Hum. Exp. Toxicol. 9:1990;317-321.
4. Bowsher D. Paradoxical pain. Br. Med. J. 306:1993;473-474.
5. Chauvin M., Sandouk P., Scherrmann J.M., Farinotti R., Strumza P., Duvaldestin P. Morphine pharmacokinetics in renal failure. Anesthesiology. 66:1987;327-331.
6. Christensen C.B., Jorgensen L.N. Morphine-6-glucuronide has high affinity for the opioid receptor. Pharmacol. Toxicol. 60:1987;75-76.
7. Coffman B.L., Rios G.R., King C.D., Tephly T.R. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab. Dispos. 25:1997;1-4.
8. Coughtrie M.W.H., Ask B., Rane A., Burchell B., Hume R. The enantioselective glucuronidation of morphine in rats and humans. Biochem. Pharmacol. 38:1989;3273-3280.
9. Ellison N.M., Lewis G.O. Plasma concentrations following single doses of morphine sulfate in oral solution and rectal suppository. Clin. Pharm. 3:1984;614-617.
10. Expert Working Group of the European Association for Palliative Care, Morphine in cancer pain: modes of administration, Br. Med. J., 312 (1996) 823-826.
11. Faura, C.C., Moore, R.A., Horga, J.F., Hand, C.W. and McQuay, H.J., Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain, J. Pain Sympt. Manage., 11 (1996a) 95-102.
12. Faura, C.C., Olaso, M.J., Cabanes, C.G. and Horga, J.F., Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved?, Pain, 65 (1996b) 25-30.
13. Glare P.A., Walsh T.D. Clinical pharmacokinetics of morphine. Ther. Drug Monit. 13:1991;1-23.
14. Gong Q.L., Hedner T., Hedner J., Björkman R., Nordberg G. Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide. Eur. J. Pharmacol. 193:1991;47-56.
15. Gong Q.L., Hedner T., Hedner J., Björkman R., Hedner T. Morphine-3-glucuronide may functionally antagonise morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain. 48:1992;249-255.
16. Hanks G.W., Aherne G.W., Hoskin P.J., Turner P., Poulain P. Explanation for potency of repeated oral doses of morphine. Lancet. 2:1987;723-724.
17. Hanna M.H., Peat S.J., Woodham M., Knibb A., Fung C. Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br. J. Anaesth. 64:1990;547-550.
18. Hanna M.H., D'Costa F., Peat S.J., Fung C., Venkat N., Zilkha T.R., Davies S. Morphine-6-glucuronide disposition in renal impairment. Br. J. Anaesth. 70:1993;511-514.
19. Hewett K., Dickenson A.H., McQuay H.J. Lack of effect of morphine-3-glucuronide on the spinal antinociceptive actions of morphine in the rat: an electrophysiological study. Pain. 53:1993;59-63.
20. Hoskin P.J., Hanks G.W., Aherne G.W., Chapman D., Littleton P., Filshie J. The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Br. J. Clin. Pharmacol. 27:1989;499-505.
21. Inturrisi C.E., Max M., Umans J., Schultz M., Shin S., Foley K.M., Houde R. The pharmacokinetics of heroin in patients with chronic pain. N. Engl. J. Med. 310:1984;1213-1217.
22. Jadad A.R., Carroll D., Moore A., McQuay H.J. Developing a database of published reports of randomised clinical trials in pain research. Pain. 66:1996;239-246.
23. Joel S.P., Osborne R.J., Nixon N.S., Slevin M.L. Morphine-6-glucuronide, an important metabolite. Lancet. 1:1985;1099-1100.
24. Koren G., Butt W., Chinyanga H., Soldin S., Tan Y.K., Pape K. Post-operative morphine infusion in newborn infants: assessment of disposition characteristics and safety. J. Paediatr. 107:1985;963-967.
25. Lynn A.M., Slattery J.T. Morphine pharmacokinetics in early infancy. Anesthesiology. 66:1987;136-139.
26. McQuay H., Moore A. Be aware of renal function when prescribing morphine. Lancet. 2:1984;284-285.
27. McQuay, H.J. and Moore, R.A., Opioid problems, and morphine metabolism and excretion. In: A.H. Dickenson and J.M. Besson (Eds.), Handbook of Experimental Pharmacology, 130, Springer Verlag, Berlin, 1997, pp. 335-360.
28. McQuay H.J., Carroll D., Faura C.C., Gavaghan D.J., Hand C.W., Moore R.A. Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin. Pharmacol. Ther. 48:1990;236-244.
29. McRorie T.I., Lynn A.M., Nespeca M.K., Opheim K.E., Slattery J.T. The maturation of morphine clearance and metabolism. Am. J. Dis. Child. 146:1992;972-976.
30. Milne R.W., Nation R.L., Somogyi A.A., Bochner F., Griggs W.M. The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients. Br. J. Clin. Pharmacol. 34:1992;53-59.
31. Milne R.W., Nation R.L., Somogyi A.A. The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab. Rev. 28:1996;345-372.
32. Oguri, K., Conjugated metabolites of morphine and their pharmacological activity, Yakugaku Zasshi, 100 (1980) 117-125.
33. Olkkola K.T., Hamunen K., Maunuksela E.L. Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children. Clin. Pharmacokinet. 28:1995;385-404.
34. Osborne R.J., Joel S.P., Slevin M.L. Morphine intoxication in renal failure: the role of morphine-6- glucuronide. Br. Med. J. 292:1986;1548-1549.
35. Osborne R., Joel S., Trew D., Slevin M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin. Pharmacol. Ther. 47:1990;12-19.
36. Osborne R., Thompson P., Joel S., Trew D., Patel N., Slevin M. The analgesic activity of morphine-6-glucuronide. Br. J. Clin. Pharmacol. 34:1992;130-138.
37. Osborne R., Joel S., Grebenik K., Trew D., Slevin M. The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin. Pharmacol. Ther. 54:1993;158-167.
38. Pasternak G.W., Bodnar R.J., Clark J.A., Inturrisi C.E. Morphine-6-glucuronide, a potent mu agonist. Life Sci. 41:1987;2845-2849.
39. Peterson G.M., Randall C.T.C., Paterson J. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur. J. Clin. Pharmacol. 38:1990;121-124.
40. Pokela M.L., Olkkola K.T., Seppala T., Koivisto M. Age-related morphine kinetics in infants. Dev. Pharmacol. Ther. 20:1993;26-34.
41. Portenoy R.K., Foley K.M., Stulman J., Khan E., Adelhardt J., Layman M., Cerbone D.F., Inturrisi C.E. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain. 47:1991;13-19.
42. Portenoy R.K., Thaler H.T., Inturrisi C.E., FriedlanderKlar H., Foley K.M. The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. Clin. Pharmacol. Ther. 51:1992;422-431.
43. Salmon, W., Dora Medicum, 2nd edn., London, 1688.
44. Sandouk P., Serrie A., Scherrmann J.M., Langlade A., Bourre J.M. Presence of morphine metabolites in human cerebrospinal fluid after intracerebroventricular administration of morphine. Eur. J. Drug. Metab. Pharmacokinet. 3:1991;166-171.
45. Schulz R., Goldstein A. Inactivity of narcotic glucuronides as analgesics and on guinea-pig ileum. J. Pharmacol. Exp. Ther. 183:1972;404-410.
46. Shimomura K., Kamata O., Ueki S., Ida S., Oguri K., Yoshimura H., Tsukamoto H. Analgesic effect of morphine glucuronides. Tohoku J. Exp. Med. 105:1971;45-52.
47. Smith M.T., Watt J.A., Cramond T. Morphine-3-glucuronide - a potent antagonist of morphine analgesia. Life Sci. 47:1990;579-585.
48. Sullivan A.F., McQuay H.J., Bailey D., Dickenson A.H. The spinal antinociceptive actions of morphine metabolites morphine-6-glucuronide and normorphine in the rat. Brain Res. 482:1989;219-224.
49. Suzuki N., Kalso E., Rosenberg P.H. Intrathecal morphine-3-glucuronide does not antagonize spinal antinociception by morphine or morphine-6-glucuronide in rats. Eur. J. Pharmacol. 249:1993;247-250.
50. Toogood F. The use of morphia in cardiac disease. Lancet. 2:1898;1393-1394.
51. Wolff T., Samuelsson H., Hedner T. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration. Pain. 62:1995;147-154.
52. Yeo I. On the use of opium in acute and chronic diseases. Practitioner. 1:1907;625-640.
53. Yue Q., von Bahr C., Odar-Cederloff I., Sawe J. Glucuronidation of codeine and morphine in human liver and kidney microsomes: effect of inhibitors. Pharmacol. Toxicol. 66:1990;221-226.